Dr. Ari Kellen is a MBA graduate of distinction with decades of experience in the healthcare industry as a strategic corporate executive and a consultant. As the senior partner at McKinsey & Company, Dr. Ari Kellen directed performance turnarounds and led a variety of studies for healthcare companies. Currently, Dr. Kellen is responsible for his company’s US Dermatology, Bausch & Lomb, and Latin America businesses as executive vice president for Valeant Pharmaceuticals, where he has overseen several strategic acquisitions.
In 2015, Valeant and Bausch & Lomb acquired Acrivet, a company specializing in ophthalmology products for animals. Previously, Acrivet was the veterinary division of S&V Technologies GmbH. The acquisition was designed to reflect Bausch & Lomb’s commitment to expand into and serve the needs of the veterinary market.
Acrivet’s product line focuses on animal products and includes products ranging from intraocular lenses and bandage contact lenses to hyaluronate eye gel. These products are spread across several categories, which include corneal care, diagnostics, surgery, ophthalmic instruments, and general equipment. For additional information on the Acrivet product line, visit www.bausch.com/ecp/our-products/veterinary-ophthalmology.
In 2015, Valeant and Bausch & Lomb acquired Acrivet, a company specializing in ophthalmology products for animals. Previously, Acrivet was the veterinary division of S&V Technologies GmbH. The acquisition was designed to reflect Bausch & Lomb’s commitment to expand into and serve the needs of the veterinary market.
Acrivet’s product line focuses on animal products and includes products ranging from intraocular lenses and bandage contact lenses to hyaluronate eye gel. These products are spread across several categories, which include corneal care, diagnostics, surgery, ophthalmic instruments, and general equipment. For additional information on the Acrivet product line, visit www.bausch.com/ecp/our-products/veterinary-ophthalmology.
